Position
First Command Advisory Services, Inc. in Regeneron Pharmaceuticals, Inc.
Back to the book · All holders of REGN
Estimated mark uses implied 13F prices (value ÷ shares). Adds are treated as happening at this quarter’s mark; cuts at last quarter’s. Share jumps can be splits, not buys. This is not realized P&L.
Latest estimated mark $4$771.80 → $772.60
| Quarter | Shares | Value | Implied px | Est. mark | Flow | Weight |
|---|---|---|---|---|---|---|
| Q4 2025 | 5 | $3.86K | — | — | — | 0.0% |
| Q1 2026 | 5 | $3.86K | $772.60 | $4 | −$0 | 0.0% |